Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1997)	1/1/2004 6:07:57 PM
From: software salesperson	Read Replies (1) \| Respond to of 3044

Did the Taisho program bite the dust permanently, when 977 (CytoMed ----> LeukoSite ----> MLNM) died? from the 10/15/02 earnings press release: MLN977: As previously announced, although the oral formulation of MLN977 showed evidence of clinical benefit in patients with chronic asthma, Millennium and its development collaborator, Taisho Pharmaceuticals Co., Ltd., have discontinued the program. While Millennium is investigating other partnership options for aerosol delivery of MLN977, Taisho is not interested in pursuing this option and as a result, the collaboration with Taisho has been terminated.